时间：2016年10月2日 14：00- 16:00
地点：MIT Tang Center (E51) Room-151
70 Memorial Dr, Cambridge, MA 02142
陈寅（808）：Director of Business Development at Accelagen, Founder/President/CEO at MTT Pharmaceuticals
张引（813）： Co-founder and chairman of the law firm of Milstein Zhang & Wu LLC
王晖（9208）：CFA， Managing and Founding Partner of HighLight Capital
4.现场联系人 霍宇达（0508）： 6176786876
Dr. Yin Chen is a biotech entrepreneur with over 15 experiences in the industry. After serving as Chief Scientific Officer in a biotech company for 9 years, he co-foundered and became President/CEO of MTT Pharmaceuticals in 2008. Dr. Chen is currently consulting for several US and international pharmaceutical companies for product marketing, business development and fund raising.
Dr. Chen received his Bachelor of Science degree from University of Science & Technology China, Master of Science degree from Shanghai Institute of Biochemistry and Ph.D degree from University of Maine. He subsequently completed his postdoc training at Beth Israel Deaconess Medical Center/Harvard Medical School. In 2013, Dr. Chen earned his EMBA from Jack Welch Management Institute.
Dr. Philip Zhang is co-founder and chairman of the law firm of Milstein Zhang & Wu LLC. Dr. Zhang is a licensed lawyer and a registered patent attorney. He has practiced law in the U.S. for 17 years. Dr. Zhang has extensive experience representing pharmaceutical, biotechnology, clean technology, advanced materials, medical devices, and scientific instruments companies, including advising clients on IP strategies, product patent clearance, licensing and patent preparation and prosecution. Dr. Zhang also helps clients with IP issues in R&D collaborations, venture funding, mergers and acquisitions, and other corporate transactions. He is a frequent speaker and has published extensively on various legal, IP and technology issues including three articles in the journal Nature Biotechnology.
Dr. Zhang received his J.D. from Vanderbilt University Law School and his Ph.D. from Dartmouth College. He graduated with a B.Sci. from the University of Science & Technology of China.
Mr. Steven Wang is former senior partner and investment committee member of CDH. He has more than 10 years of experience in the medical industry and healthcare investment and focuses exclusively on healthcare services, medical device and pharmaceutical sectors. Prior to CDH, Mr. Wang served at Avenue Capital, Lehman Brothers (London) and Becton Dickinson Group. Over the last ten years, Mr. Wang was responsible for transactions totaling more than one billion dollars, including mergers & acquisitions, restructuring of publicly listed companies, growth and early stage investments.
Some of Mr. Wang’s representative deals include Kanghong Pharm (002773), KangNing Hospital (HK.02120), New Eyes (430140), Yuwell (002223), Syn The All Pharmaceutical(832159), Linwha(835637), TriPath Imaging (Nasdaq: TPTH), Poly, New Century Hospital, Angel’s Women and Children Hospital, New Century, Malo Clinic, Quyiyuan (quyiyuan.com), Dr. Cuiyutao etc.